114 related articles for article (PubMed ID: 35091358)
1. Differential effect of body mass index (BMI) on outcomes of patients treated with docetaxel in prostate cancer - An exploratory analysis.
Verma S; Arora S; Sahoo RK; Singh P; Nayak B; Haresh KP; Das CJ; Shamim SA; Kaushal S; Batra A
Cancer Treat Res Commun; 2022; 31():100520. PubMed ID: 35091358
[TBL] [Abstract][Full Text] [Related]
2. The obesity paradox in metastatic castration-resistant prostate cancer.
Martini A; Shah QN; Waingankar N; Sfakianos JP; Tsao CK; Necchi A; Montorsi F; Gallagher EJ; Galsky MD
Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):472-478. PubMed ID: 34226662
[TBL] [Abstract][Full Text] [Related]
3. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
4. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.
Pei X; Wu K; Sun Y; Gao X; Gou X; Xu J; Gao F; He D; Li L;
Urol Oncol; 2020 Jan; 38(1):2.e11-2.e17. PubMed ID: 31672485
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel.
Buttigliero C; Tucci M; Vignani F; Di Stefano RF; Leone G; Zichi C; Pignataro D; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Clin Genitourin Cancer; 2018 Aug; 16(4):318-324. PubMed ID: 29866495
[TBL] [Abstract][Full Text] [Related]
6. Effect of body mass index on survival of patients with stage I non-small cell lung cancer.
Xie HJ; Zhang X; Wei ZQ; Long H; Rong TH; Su XD
Chin J Cancer; 2017 Jan; 36(1):7. PubMed ID: 28069048
[TBL] [Abstract][Full Text] [Related]
7. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide.
Buttigliero C; Tucci M; Sonetto C; Vignani F; Di Stefano RF; Pisano C; Turco F; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Minerva Urol Nefrol; 2020 Dec; 72(6):737-745. PubMed ID: 32284527
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
Puente J; González-Del-Alba A; Sala-Gonzalez N; Méndez-Vidal MJ; Pinto A; Rodríguez Á; Cuevas Sanz JM; Muñoz Del Toro JR; Useros Rodríguez E; García García-Porrero Á; Vázquez S
BMC Cancer; 2019 Aug; 19(1):766. PubMed ID: 31382926
[TBL] [Abstract][Full Text] [Related]
10. Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials.
Chen H; Qian X; Tao Y; Wang D; Wang Y; Yu Y; Yao H
Breast; 2023 Oct; 71():1-12. PubMed ID: 37429049
[TBL] [Abstract][Full Text] [Related]
11. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
12. PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration-resistance prostate cancer patients treated with docetaxel.
Shi X; Pei X; Fan J; Liu T; Zhang D; Yang T; Wu K; He D; Li L
Andrologia; 2021 May; 53(4):e13916. PubMed ID: 33591598
[TBL] [Abstract][Full Text] [Related]
13. Association of Body Mass Index With Outcomes Among Patients With Head and Neck Cancer Treated With Chemoradiotherapy.
Ma SJ; Khan M; Chatterjee U; Santhosh S; Hashmi M; Gill J; Yu B; Iovoli A; Farrugia M; Wooten K; Gupta V; McSpadden R; Yu H; Kuriakose MA; Markiewicz MR; Al-Afif A; Hicks WL; Seshadri M; Ray AD; Repasky E; Singh AK
JAMA Netw Open; 2023 Jun; 6(6):e2320513. PubMed ID: 37368400
[TBL] [Abstract][Full Text] [Related]
14. Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.
Desmedt C; Fornili M; Clatot F; Demicheli R; De Bortoli D; Di Leo A; Viale G; de Azambuja E; Crown J; Francis PA; Sotiriou C; Piccart M; Biganzoli E
J Clin Oncol; 2020 Sep; 38(25):2883-2891. PubMed ID: 32614702
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry.
Lammers SWM; Thurisch H; Vriens IJH; Meegdes M; Engelen SME; Erdkamp FLG; Dercksen MW; Vriens BEPJ; Aaldering KNA; Pepels MJAE; van de Winkel LMH; Peters NAJB; Tol J; Heijns JB; van de Wouw AJ; Teeuwen NJA; Geurts SME; Tjan-Heijnen VCG
Breast Cancer Res Treat; 2024 Jan; 203(2):339-349. PubMed ID: 37878148
[TBL] [Abstract][Full Text] [Related]
16. Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study.
Li W; Shen LJ; Chen T; Sun XQ; Zhang Y; Wu M; Shu WH; Chen C; Pan CC; Xia YF; Wu PH
Chin J Cancer; 2016 Aug; 35(1):75. PubMed ID: 27507261
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY
Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919
[TBL] [Abstract][Full Text] [Related]
18. Combination of body mass index and albumin predicts the survival in metastatic castration-resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials.
Pan J; Wang J; Wei Y; Zhang T; Zhang S; Ye D; Zhu Y
Cancer Med; 2021 Oct; 10(19):6697-6704. PubMed ID: 34414685
[TBL] [Abstract][Full Text] [Related]
19. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Vidal AC; Howard LE; de Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Freedland SJ
BJU Int; 2018 Jul; 122(1):76-82. PubMed ID: 29521009
[TBL] [Abstract][Full Text] [Related]
20. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
